<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>We investigated the efficacy of combination therapy using bone marrow-derived mesenchymal stromal cells (MSC) and Infliximab (IFX) to achieve “deep remission” in patients with luminal Crohn disease (CD). Our study included 72 patients (age 19–62 years) (Ме = 29) with luminal CD. Patients in the 1st group (n = 21) received standard 5-aminosalicylic acid (5-ASA) and glucocorticosteroid therapy in combination with MSC. Patients in the 2nd group (n = 32) were prescribed anti-cytokine therapy IFX. Patients in the 3rd group (n = 19) received MSC and IFX. Clinical and immunobiological (C-reactive protein-CRP and faecal calprotectin-FCP) showed a more significant decrease of local and systemic inflammation activity in the 3rd group of patients. During a 5-year follow-up we observed longer duration of remission in patients who received MSC and IFX compared to the 1st (<italic>р</italic> = 0,04) and 2nd groups of patients (<italic>р</italic> = 0.038). Combination therapy of bone marrow-derived MSC and IFL provides “deep remission” in patients with luminal CD and has higher prognostic value for duration of CD remission period.</p>
</abstract>

We investigated the efficacy of combination therapy using bone marrow-derived mesenchymal stromal cells (MSC) and Infliximab (IFX) to achieve “deep remission” in patients with luminal Crohn disease (CD). Our study included 72 patients (age 19–62 years) (Ме = 29) with luminal CD. Patients in the 1st group (n = 21) received standard 5-aminosalicylic acid (5-ASA) and glucocorticosteroid therapy in combination with MSC. Patients in the 2nd group (n = 32) were prescribed anti-cytokine therapy IFX. Patients in the 3rd group (n = 19) received MSC and IFX. Clinical and immunobiological (C-reactive protein-CRP and faecal calprotectin-FCP) showed a more significant decrease of local and systemic inflammation activity in the 3rd group of patients. During a 5-year follow-up we observed longer duration of remission in patients who received MSC and IFX compared to the 1st (р = 0,04) and 2nd groups of patients (р = 0.038). Combination therapy of bone marrow-derived MSC and IFL provides “deep remission” in patients with luminal CD and has higher prognostic value for duration of CD remission period.

Mesenchymal stem cell therapy in patients with Crohn’s disease — 5 year follow-up

Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

We investigated the efficacy of combination therapy using bone marrow-derived mesenchymal stromal cells (MSC) and Infliximab (IFX) to achieve “deep remission”...

Mesenchymal stem cell therapy in patients with Crohn’s disease — 5 year follow-up

Online veröffentlicht: 10. Dez. 2022

Seitenbereich: 618 - 622

DOI: https://doi.org/10.2478/prolas-2022-0095

Schlüsselwörter
Crohn’s disease, inflammatory bowel disease, infliximab, mesenchymal stromal cells

© 2022 Oleg V. Knyazev et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Mesenchymal stem cell therapy in patients with Crohn’s disease — 5 year follow-up

Online veröffentlicht: 10. Dez. 2022

Seitenbereich: 618 - 622

DOI: https://doi.org/10.2478/prolas-2022-0095

SchlüsselwörterCrohn’s disease, inflammatory bowel disease, infliximab, mesenchymal stromal cells

© 2022 Oleg V. Knyazev et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Schlüsselwörter
Crohn’s disease, inflammatory bowel disease, infliximab, mesenchymal stromal cells